Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Completed · Phase 1 · NCT03028103
Conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone Lymphoma
At a glance
- Research payments reported, 2025
- $38,489
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- Epizyme, Inc.
- Tested
- Tazemetostat (drug), Fluconazole (drug), Omeprazole (drug), Repaglinide (drug)
- Dates
- Started 2017-03-27; completion 2019-11-29
- Results posted
- Yes
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.
From ClinicalTrials.gov, last updated 2023-06-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $38,489 in research payments for this study in 2025 (4 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Trustees of Columbia University in The City of New York $38,489
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.